BMY Oct 2024 46.000 put
| Previous Close | 4.8500 |
| Open | 4.8600 |
| Bid | 4.8000 |
| Ask | 5.3000 |
| Strike | 46.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 4.8500 - 4.8600 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 488 |
- ACCESSWIRE
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to expand access to immuno-oncology therapy Opdivo™ in select countries PRINCETON, NJ / ACCESSWIRE / May 22, 2024 /Bristol Myers Squibb (NYSE:BMY) ...
PR NewswireNeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round.
- Associated Press Finance
Hawaii court orders drug companies to pay $916 million in Plavix blood thinner lawsuit
A Hawaii court has ordered the manufacturers and distributors of the blood thinner Plavix to pay the state a combined $916 million after finding the companies failed to disclose the efficacy and safety of the medication, the state attorney general said Tuesday. The judgement was issued against Bristol Myers Squibb Company and three U.S.-based subsidiaries of French pharmaceutical company Sanofi. Bristol Myers Squibb and Sanofi said in a joint statement they disagreed with the penalty and plan to appeal.
